NewsCorporate ActionsVenmax Drugs Allots 7.75 Lakh Equity Shares Through Warrant Conversion Worth ₹1.16 CroresVenmax Drugs Allots 7.75 Lakh Equity Shares Through Warrant Conversion Worth ₹1.16 Crores
Venmax Drugs and Pharmaceuticals Limited allotted 7,75,000 equity shares on January 21, 2026, through warrant conversion by three non-promoter investors. The conversion was executed at ₹20 per share, generating ₹1,16,25,000 in proceeds and increasing the company's paid-up capital to ₹8,78,29,300. With 64,81,000 warrants still outstanding from the original March 2025 issuance, the company maintains potential for further capital expansion through future conversions.
*this image is generated using AI for illustrative purposes only.
Venmax drugs & pharmaceuticals Limited has completed the allotment of 7,75,000 equity shares through warrant conversion on January 21, 2026. The Board of Directors approved the conversion after three warrant holders exercised their conversion rights, originally allotted warrants on March 20, 2025.
Warrant Conversion Details
The allotment involved conversion of warrants at an issue price of ₹20 per share, comprising face value of ₹10 and premium of ₹10 each. The warrant holders paid the balance exercise price of ₹15 per warrant, representing 75% of the total warrant exercise price, aggregating to ₹1,16,25,000.
| Parameter: | Details |
|---|---|
| Total Shares Allotted: | 7,75,000 |
| Issue Price per Share: | ₹20.00 |
| Face Value: | ₹10.00 |
| Premium: | ₹10.00 |
| Total Consideration: | ₹1,16,25,000 |
| Conversion Ratio: | 1:1 |
Allottee Breakdown
All three warrant holders who exercised conversion rights belong to the non-promoter category. The conversion was executed on a 1:1 basis, with each warrant converting into one equity share.
| Allottee Name: | Category | Warrants Held | Shares Allotted |
|---|---|---|---|
| Sankalp Sunil Wakkar: | Non-Promoter | 1,25,000 | 1,25,000 |
| I2 Pro Services Pvt Ltd: | Non-Promoter | 1,00,000 | 1,00,000 |
| Manish Grover: | Non-Promoter | 5,50,000 | 5,50,000 |
| Total: | 7,75,000 | 7,75,000 |
Impact on Share Capital
Following the allotment, the company's paid-up capital has increased substantially. The new capital structure reflects the successful conversion of a portion of the outstanding warrants issued under the preferential allotment scheme.
| Capital Parameter: | Amount/Number |
|---|---|
| New Paid-up Capital: | ₹8,78,29,300 |
| Total Equity Shares: | 87,82,930 |
| Face Value per Share: | ₹10.00 |
Outstanding Warrants
The conversion represents partial utilization of the total warrants issued. Out of the original 1,00,25,000 warrants allotted in March 2025, a significant portion remains available for future conversion by other warrant holders.
| Warrant Status: | Number |
|---|---|
| Original Warrants Issued: | 1,00,25,000 |
| Warrants Converted: | 7,75,000 |
| Outstanding Warrants: | 64,81,000 |
The allotment was conducted under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, following preferential allotment norms. The Board meeting for approving the conversion commenced at 4:00 PM and concluded at 5:00 PM on January 21, 2026.
Historical Stock Returns for Venmax Drugs & Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.15% | -5.46% | -10.14% | -1.94% | +5.65% | +292.10% |
19
